HopeStage
Back to all studies
Not Yet RecruitingNCT07686731

Suvorexant 3 - PE-PC

Medication studyAges 18–75United StatesPTSD
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 75 years.

Listed locations
San FranciscoSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateEstimated: September 1, 2026
Recruitment status
Not Yet Recruiting
Enrollment listed in the registry
142
Sponsor
Northern California Institute of Research and Education
Sponsor type
Research institute
Study type
Behavioral
Intervention type
Behavioural, Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 75 Years
Official registry ID
NCT07686731
Official title
Show the full official title

Suvorexant: Targeting Orexin to Augment Exposure Therapy in Veterans With PTSD and Insomnia

Recruitment & locations

Not yet recruiting

San Francisco

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Northern California Institute of Research and Education, a research institute.

Does this study involve medication?

Yes. The study involves medication, including Suvorexant and Placebo.

Who can participate?

Listed age limits: 18 years to 75 years.

Is this study still recruiting?

The registry lists this study as not yet recruiting.

Want to explore more studies?

Explore studies